Dynamic List Information
Dynamic List Data
Title
RESCIND The Importance of Timely Use of COVID-19 Therapeutics
Memo #
QSO-23-03-All RESCINDED as of 01/20/2025
Posting Date
2025-03-14
Title
CMS is rescinding this memo (QSO-23-03-All), effective on 01/20/2025 as referenced in Executive Order 13997.
Providers and suppliers, especially those delivering care in congregate care settings, should ensure their patients and residents are protected against transmission of COVID-19 within their facilities, as well as receiving appropriate treatment when tested positive for the virus.
Further, all providers and suppliers should continue to implement appropriate infection control protocols for COVID-19 (https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection- control.html) and Influenza (https://www.cdc.gov/flu/professionals/infectioncontrol/index.htm).
This memo discusses the importance of the timely use of available COVID-19 therapeutics, particularly for high-risk patients who test positive for the virus.
Providers and suppliers, especially those delivering care in congregate care settings, should ensure their patients and residents are protected against transmission of COVID-19 within their facilities, as well as receiving appropriate treatment when tested positive for the virus.
Further, all providers and suppliers should continue to implement appropriate infection control protocols for COVID-19 (https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection- control.html) and Influenza (https://www.cdc.gov/flu/professionals/infectioncontrol/index.htm).
This memo discusses the importance of the timely use of available COVID-19 therapeutics, particularly for high-risk patients who test positive for the virus.